ArticleJournal of clinical medicine2020

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial.

Louise Vedtofte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.